PDSB
PDS Biotechnology Corp
NASDAQ · Healthcare · Biotechnology · US
$1.30
−7.80%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$1.47
From 52W high−18.75%
Volume4.51M
Market cap$94.22M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$1.47
From 52W high
−18.75%
Volume
4.51M
Market cap
$94.22M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.4x
P/E (TTM)
—
RSI (14)
53.8
MomentumView details →
1D Return
−7.80%
YTD Return
+66.41%
SummaryUpdated Jun 1, 2026
PDS Biotechnology Corporation (NASDAQ:PDSB) is a clinical-stage biopharmaceutical company founded in 2005 and headquartered in Florham Park, New Jersey. The company focuses on developing multifunctional cancer immunotherapies using its proprietary Versamune platform technology. Since going public in 2015, PDS has advanced multiple product candidates through clinical trials, with its lead program targeting HPV-positive cancers currently in Phase 3 development. The company operates as a pure-play biotechnology firm with no current revenue, relying on clinical trial advancement and potential partnerships to drive value creation.
Similar companies
Latest newsMore news →
PDS Biotechnology's 50-day simple moving average crossed above its 200-day simple moving average, forming a golden cross.6h agoPDS Biotechnology Corp amended its $6,000,000 promissory note with YA II PN, Ltd., modifying payment and cure-period terms, including a mandatory deemed redemption of proceeds from non-ATM equity financings.61d agoPDS Biotechnology filed a prospectus to register the sale of up to 13.32 million shares of common stock by selling stockholders; the company will not receive any proceeds.117d ago